Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Opus Genetics (IRD) received FDA approval for phentolamine ophthalmic solution 0.75% to treat presbyopia, an age-related vision condition. The approval follows positive Phase 3 trial results and triggers a milestone payment. Viatris holds U.S. commercialization rights. The drug is marketed as RYZUMVI, with presbyopia as a new indication.

Original reporting
Published Oct 16, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 17, 2026, 4:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia — source image
Decision brief

The 30-second read

$IRDBullishMed
01

Why it matters

The FDA label expansion is supported by positive pivotal Phase 3 VEGA-2 and VEGA-3 results and is expected to trigger a milestone payment to Opus Genetics, improving the commercialization outlook for the product in the US.

02

Market read

Traders may reassess IRD’s regulatory execution and near-term cash-flow catalysts tied to the presbyopia approval milestone.

03

What to watch

The press release does not quantify expected sales ramp, pricing, or the size/timing of the milestone payment, which could limit how far the stock can re-rate without follow-on financial guidance.

Relevance 9/10Novelty 9/10Timing: today’s FDA approval headline, after-hours/close depending on local market timing

Background

Opus Genetics announced FDA approval of a supplemental NDA for phentolamine ophthalmic solution 0.75% (marketed as RYZUMVI) to include presbyopia in adults.

Company-level read

Ticker impact

$IRDBullishHigh confidence
Context

Opus Genetics (IRD) received FDA approval of an sNDA expanding phentolamine ophthalmic solution 0.75% to treat presbyopia in adults.

Expected impact

Likely positive repricing as investors price in incremental revenue potential and the disclosed milestone payment trigger.

Evidence & confidence

The article is a first-report FDA approval for IRD’s supplemental application, supported by pivotal Phase 3 VEGA-2/VEGA-3 results, and it explicitly states a presbyopia approval will trigger a milestone payment to Opus Genetics.

Market effects

Adds incremental validation for ophthalmic pharmacology and for Opus’s ability to execute regulatory milestones beyond gene therapy.

Limited, as the event is US FDA label expansion for a specific product.

Moderate, since the licensing agreement is described as global and the US commercialization rights are central to near-term economics.

Counterpoint

The approval is for an ophthalmic indication expansion of an already-marketed product, so upside may be capped versus a brand-new asset launch.

Key entities

  • Opus Genetics, Inc.

    Clinical-stage biopharmaceutical company; subject of the FDA supplemental approval announcement.

  • Viatris Inc.

    Licensing partner with exclusive US commercialization rights for phentolamine ophthalmic solution 0.75%.

  • U.S. Food and Drug Administration (FDA)

    Approved the supplemental NDA expanding the indication to presbyopia in adults.

Related articles

$IRDHighAI 8/10

Opus Genetics Announces Financial Results for Third Quarter 2026 and Provides Corporate Update

Opus Genetics, Inc. (IRD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Opus Genetics Announces Financial Results for Third Quarter 2026 and Provides Corporate Update OPGx-BEST1 Cohort 2 Dosing Complete and Data Expected in Q1 2027 OPGx-LCA5 Registrational Phase 3 Trial Fully Enrolled with Initiation of Dosing Expected in Q4 2026 FDA Cle

$IRDMedAI 8/10

Opus Genetics completes dosing in gene therapy trial cohort

Opus Genetics (IRD) completed dosing in Cohort 2 of its BIRD-1 trial for OPGx-BEST1, treating 11 participants with a higher dose than Cohort 1. Data is expected in Q1 2027, with Phase 3 potentially starting in H2 2027. Cohort 1 showed improvements in visual measures with no serious adverse events. The FDA aligned on a pivotal endpoint for the therapy, which targets BEST1-related retinal diseases with no current approved treatments.

$IRDMedAI 8/10

Opus Genetics Eyes 2029 Runway as Presbyopia Drop Wins FDA Approval

Opus Genetics (NASDAQ:IRD) is advancing clinical trials for gene therapies OPGx-LCA5 and OPGx-BEST1. The company expects data readouts by late 2024 and projects a cash runway into 2029. Opus estimates addressable populations of 150-200 for LCA5 and 23,600 for BEST1 in the U.S. Management anticipates potential priority review vouchers and plans to prioritize programs based on clinical evidence.

$IRDMedAI 8/10

Opus Genetics receives FDA clearance for RDH12-LCA gene therapy

Opus Genetics (NASDAQ:IRD) received FDA clearance for its gene therapy OPGx-RDH12, targeting RDH12-associated Leber congenital amaurosis. The company plans to start a Phase 1/2 trial this quarter. The therapy aims to restore retinal function in a rare inherited disease affecting 30,900 people globally. Opus Genetics collaborates with the Global RDH12 Alliance, which committed up to $1.6 million for development.